JP Morgan Chase
PRQR icon

JP Morgan Chase’s ProQR Therapeutics PRQR Stock Holding History

JP Morgan Chase’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$427 Hold
283
– – ﹤0.01% 7191
2025
Q4 		$572 Sell
283
-185
-40% -$432 ﹤0.01% 7072
2025
Q3 		$997 Sell
468
-2,877
-86% -$6.29K ﹤0.01% 6987
2025
Q2 		$6.82K Sell
3,345
-749
-18% -$1.22K ﹤0.01% 6373
2025
Q1 		$5.45K Sell
4,094
-49,329
-92% -$105K ﹤0.01% 6422
2024
Q4 		$142K Buy
53,423
+53,123
+17,708% +$169K ﹤0.01% 5618
2024
Q3 		$546 Sell
300
-14
-4% -$26 ﹤0.01% 6794
2024
Q2 		$521 Sell
314
-1,179
-79% -$2.29K ﹤0.01% 6685
2024
Q1 		$3.39K Sell
1,493
-321
-18% -$686 ﹤0.01% 6507
2023
Q4 		$3.59K Sell
1,814
-145,691
-99% -$224K ﹤0.01% 6619
2023
Q3 		$192K Sell
147,505
-32,892
-18% -$51.7K ﹤0.01% 5090
2023
Q2 		$292K Sell
180,397
-42,179
-19% -$82.4K ﹤0.01% 4839
2023
Q1 		$474K Buy
222,576
+220,778
+12,279% +$675K ﹤0.01% 4538
2022
Q4 		$7K Sell
1,798
-3,033
-63% -$3.97K ﹤0.01% 6102
2022
Q3 		$4K Sell
4,831
-959,883
-99% -$771K ﹤0.01% 6150
2022
Q2 		$750K Sell
964,714
-13,080
-1% -$9.75K ﹤0.01% 4289
2022
Q1 		$885K Buy
977,794
+268,315
+38% +$899K ﹤0.01% 4357
2021
Q4 		$5.68M Sell
709,479
-241,581
-25% -$1.84M ﹤0.01% 2951
2021
Q3 		$7.96M Sell
951,060
-66,226
-7% -$433K ﹤0.01% 2606
2021
Q2 		$6.86M Buy
1,017,286
+131,731
+15% +$849K ﹤0.01% 2764
2021
Q1 		$5.85M Buy
885,555
+280,378
+46% +$1.43M ﹤0.01% 2835
2020
Q4 		$2.54M Buy
605,177
+284,605
+89% +$1.2M ﹤0.01% 3310
2020
Q3 		$1.54M Buy
320,572
+68,141
+27% +$356K ﹤0.01% 3400
2020
Q2 		$1.53M Buy
252,431
+113,113
+81% +$611K ﹤0.01% 3271
2020
Q1 		$765K Buy
139,318
+88,304
+173% +$677K ﹤0.01% 3583
2019
Q4 		$505K Buy
+51,014
New +$397K ﹤0.01% 4232
2019
Q3 		– Sell
-656
Closed -$6K – 5908
2019
Q2 		$6K Sell
656
-12,119
-95% -$143K ﹤0.01% 5619
2019
Q1 		$177K Buy
+12,775
New +$191K ﹤0.01% 4672
2018
Q2 		– Sell
-33,425
Closed -$103K – 5657
2018
Q1 		$103K Buy
33,425
+28,025
+519% +$90.2K ﹤0.01% 4576
2017
Q4 		$17K Buy
+5,400
New +$19.4K ﹤0.01% 5188
2017
Q1 		– Sell
-3,553
Closed -$17K – 5186
2016
Q4 		$17K Sell
3,553
-8,485
-70% -$43.7K ﹤0.01% 4732
2016
Q3 		$80K Buy
12,038
+6,019
+100% +$33.1K ﹤0.01% 3914
2016
Q2 		$29K Buy
6,019
+3,704
+160% +$19.1K ﹤0.01% 4161
2016
Q1 		$11K Buy
+2,315
New +$11.8K ﹤0.01% 4228

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

JP Morgan Chase's PRQR Position: Q1 2026 in Review

JP Morgan Chase held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 283 shares worth $427. The position accounts for ﹤0.01% of the portfolio, ranked #7191.

JP Morgan Chase first reported a position in PRQR in Q1 2016 and has held it in 34 quarters since. The position peaked at $7.96M in Q3 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • JP Morgan Chase held 283 shares of ProQR Therapeutics worth $427 as of Q1 2026.
  • JP Morgan Chase left its ProQR Therapeutics share count unchanged in Q1 2026.
  • ProQR Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7191 holding.
  • JP Morgan Chase first reported a position in ProQR Therapeutics in Q1 2016 and has held it in 34 quarters since.
  • JP Morgan Chase's ProQR Therapeutics position peaked at $7.96M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.